This HTML5 document contains 101 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n4	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
n12	http://dx.doi.org/10.1161/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q44000678

rdf:type

wikibase:Item

schema:description

article científic 2002年學術文章 2002年学术文章 vitenskapelig artikkel 2002年学术文章 article scientifique teaduslik artikkel artigo científico научная статья artigo científico article scientific artículo científico publicado en 2002 scientific article published in May 2002 wetenschappelijk artikel vědecký článek scienca artikolo bilimsel makale 2002年学术文章 мақолаи илмӣ vitskapeleg artikkel 2002년 논문 2002年学术文章 บทความทางวิทยาศาสตร์ artikull shkencor bài báo khoa học 2002年學術文章 научни чланак artykuł naukowy naučni članak মে ২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articolo scientifico wissenschaftlicher Artikel научни чланак artigo científico επιστημονικό άρθρο tudományos cikk scientific article published in May 2002 tieteellinen artikkeli 2002年學術文章 artículu científicu espublizáu en 2002 scientific article published in May 2002 مقالة علمية نشرت في مايو 2002 2002年学术文章 artikel ilmiah სამეცნიერო სტატია videnskabelig artikel 2002 nî lūn-bûn 2002年学术文章 vetenskaplig artikel 2002年學術文章 artikulong pang-agham 2002年の論文 научна статия 2002年學術文章 articol științific наукова стаття, опублікована в травні 2002 vedecký článok מאמר מדעי

p:P577

wds:Q44000678-59AE0C7B-8E26-44FB-91CC-E1B018FEE61A

wdt:P577

2002-05-01T00:00:00Z

p:P407

wds:Q44000678-9C9CAEB2-108D-4918-A14B-049E3533FAB1

wdt:P407

wd:Q1860

p:P2093

wds:Q44000678-0A560572-E488-4959-8E7F-C28F6138D0BC wds:Q44000678-563FE19B-5500-47EF-A79B-316A811B976A wds:Q44000678-7E8FAE11-EB45-4DCE-B716-0D6F970B7137 wds:Q44000678-6FAA7A2B-9AB6-40C7-A080-0286DABDC793

wdt:P2093

Pierre Theroux Peter M DiBattiste Steven M Snapinn Ik-Kyung Jang

rdfs:label

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS

skos:prefLabel

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS

schema:name

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms

p:P50

wds:Q44000678-8A11A5C4-E886-421E-BDB0-94C5962A79F4

wdt:P50

wd:Q63144011

p:P1476

wds:Q44000678-2A54541C-908F-42B4-B2A4-4836E6114137

wdt:P1476

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS

p:P304

wds:Q44000678-F62CE23F-C2E1-4132-AB58-60B79A312877

wdt:P304

2361-2366

p:P31

wds:Q44000678-C8420E92-242F-4254-89E7-9BE1779700DD

wdt:P31

wd:Q13442814

p:P921

wds:Q44000678-6BF61AF8-B645-4A4E-B67C-4EC6BECB36CF wds:Q44000678-B2F95DF6-ECDD-4D24-A1A7-F3EB7DF973C5

wdt:P921

wd:Q181600 wd:Q266018

p:P698

wds:Q44000678-CC0A36CD-09FC-40E0-A602-DE46F5966828

wdtn:P698

n4:12021221

wdt:P698

12021221

p:P1433

wds:Q44000678-11D2CD14-44C5-4DDC-A43B-7DDCB1E1BAD9

wdt:P1433

wd:Q578091

p:P433

wds:Q44000678-0EC2A7B1-F29F-40ED-BD3F-7D76E4541401

p:P478

wds:Q44000678-A89EA3CB-D162-4FA2-AD91-D7FB4D9B3E3B

wdt:P433

20

wdt:P478

105

p:P356

wds:Q44000678-247274AF-2C31-44F8-9906-86FF76FAC573

wdtn:P356

n12:01.CIR.0000016359.94919.16

wdt:P356

10.1161/01.CIR.0000016359.94919.16